Found: 58
Select item for more details and to access through your institution.
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 639, doi. 10.1002/cpdd.750
- By:
- Publication type:
- Article
Absence of Tobramycin Pharmacokinetic and Creatinine Clearance Variation During the Menstrual Cycle: Implied Absence of Variation in Glomerular Filtration Rate.
- Published in:
- 1989
- By:
- Publication type:
- Other
Inhibition of Theophylline Elimination by Diltiazem Therapy.
- Published in:
- 1987
- By:
- Publication type:
- Other
Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Sex differences in CYP3A activity using intravenous and oral midazolam<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2006, v. 80, n. 5, p. 531, doi. 10.1016/j.clpt.2006.08.014
- By:
- Publication type:
- Article
Comparison of midazolam and simvastatin as cytochrome P450 3A probes<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2006, v. 79, n. 4, p. 350, doi. 10.1016/j.clpt.2005.11.016
- By:
- Publication type:
- Article
Evaluation of inhibitory drug interactions during drug development: Genetic polymorphisms must be considered
- Published in:
- 2005
- By:
- Publication type:
- Editorial
Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the 'Cooperstown 5+1 cocktail'<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2003, v. 74, n. 5, p. 437, doi. 10.1016/S0009-9236(03)00229-7
- By:
- Publication type:
- Article
Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2003, v. 73, n. 3, p. 209, doi. 10.1067/mcp.2003.29
- By:
- Publication type:
- Article
Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2002, v. 72, n. 6, p. 711, doi. 10.1067/mcp.2002.128866
- By:
- Publication type:
- Article
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.
- Published in:
- Clinical Pharmacology & Therapeutics, 2002, v. 72, n. 2, p. 192, doi. 10.1067/mcp.2002.126174
- By:
- Publication type:
- Article
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the 'Cooperstown cocktail'<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2000, v. 68, n. 4, p. 375, doi. 10.1067/mcp.2000.109519
- By:
- Publication type:
- Article
Is it sex or is it gender?
- Published in:
- Clinical Pharmacology & Therapeutics, 2000, v. 68, n. 1, p. 1, doi. 10.1067/mcp.2000.108356
- By:
- Publication type:
- Article
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1999, v. 66, n. 5, p. 535, doi. 10.1016/S0009-9236(99)70018-4
- By:
- Publication type:
- Article
Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1998, v. 64, n. 3, p. 269, doi. 10.1016/S0009-9236(98)90175-8
- By:
- Publication type:
- Article
Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1998, v. 64, n. 3, p. 257, doi. 10.1016/S0009-9236(98)90174-6
- By:
- Publication type:
- Article
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1998, v. 63, n. 5, p. 540, doi. 10.1016/S0009-9236(98)90105-9
- By:
- Publication type:
- Article
Menstrual cycle and renal clearance.
- Published in:
- Clinical Pharmacology & Therapeutics, 1991, v. 49, n. 5, p. 596, doi. 10.1038/clpt.1991.70
- By:
- Publication type:
- Article
Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.
- Published in:
- 2009
- By:
- Publication type:
- Letter
An Evaluation of the Atkins' Diet.
- Published in:
- Metabolic Syndrome & Related Disorders, 2003, v. 1, n. 4, p. 299, doi. 10.1089/1540419031361426
- By:
- Publication type:
- Article
S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 9, p. 1349, doi. 10.1007/s00228-021-03123-y
- By:
- Publication type:
- Article
Quantitative assessment of hepatic blood flow using intravenous indocyanine green.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.
- Published in:
- European Journal of Clinical Pharmacology, 2006, v. 62, n. 6, p. 431, doi. 10.1007/s00228-006-0124-0
- By:
- Publication type:
- Article
Authors' response: Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
- Published in:
- British Journal of Clinical Pharmacology, 2006, v. 62, n. 2, p. 187, doi. 10.1111/j.1365-2125.2006.02628.x
- By:
- Publication type:
- Article
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Evaluation of In Vivo P-Glycoprotein Phenotyping Probes.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 4, p. 223, doi. 10.2165/11318000-000000000-00000
- By:
- Publication type:
- Article
Cardiovascular risk factor burden has a stronger association with self‐rated poor health in adults in the US than in Sweden, especially for the lower educated.
- Published in:
- Scandinavian Journal of Public Health, 2006, v. 34, n. 2, p. 140, doi. 10.1080/14034940510032365
- By:
- Publication type:
- Article
Seasonal influenza vaccination and technologies.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 7, p. 719, doi. 10.1002/jcph.299
- By:
- Publication type:
- Article
Validating Phenotyping Cocktails: More Work Needs to Be Done.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 11, p. 1772, doi. 10.1177/0091270011436346
- By:
- Publication type:
- Article
Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail.
- Published in:
- Journal of Clinical Pharmacology, 2006, v. 46, n. 5, p. 577, doi. 10.1177/0091270006287291
- By:
- Publication type:
- Article
Use of Omeprazole as a CYP3A Probe Drug: Effect of Sex and Menstrual Cycle Phase on CYP3A Activity in Healthy Caucasian Adults.
- Published in:
- Journal of Clinical Pharmacology, 2006, v. 46, n. 3, p. 345, doi. 10.1177/0091270005284389
- By:
- Publication type:
- Article
Limited Sampling Models for Oral Midazolam: Midazolam Plasma Concentrations, Not the Ratio of 1-Hydroxymidazolam to Midazolam Plasma Concentrations, Accurately Predicts AUC as a Biomarker of CYP3A Activity.
- Published in:
- Journal of Clinical Pharmacology, 2006, v. 46, n. 2, p. 229, doi. 10.1177/0091270005283466
- By:
- Publication type:
- Article
The Effect of Oral Pleconaril on Hepatic Cytochrome P450 3A Activity in Healthy Adults Using Intravenous Midazolam as a Probe.
- Published in:
- Journal of Clinical Pharmacology, 2006, v. 46, n. 1, p. 103, doi. 10.1177/0091270005283286
- By:
- Publication type:
- Article
Effect of a Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail.
- Published in:
- Journal of Clinical Pharmacology, 2005, v. 45, n. 12, p. 1413, doi. 10.1177/0091270005280851
- By:
- Publication type:
- Article
Over-the-Counter Progesterone Cream Produces Significant Drug Exposure Compared to a Food and Drug Administration-Approved Oral Progesterone Product.
- Published in:
- Journal of Clinical Pharmacology, 2005, v. 45, n. 6, p. 614, doi. 10.1177/0091270005276621
- By:
- Publication type:
- Article
Lack of Weight-Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping.
- Published in:
- Journal of Clinical Pharmacology, 2004, v. 44, n. 9, p. 966
- By:
- Publication type:
- Article
Application of Bayes Theorem to Aminoglycoside-Associated Nephrotoxicity: Comparison of Extended-Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple-Daily Dosing.
- Published in:
- Journal of Clinical Pharmacology, 2004, v. 44, n. 7, p. 696
- By:
- Publication type:
- Article
Limited Sampling Strategy of S-Warfarin Concentrations, but Not Warfarin S/R Ratios, Accurately Predicts S-Warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers.
- Published in:
- Journal of Clinical Pharmacology, 2004, v. 44, n. 6, p. 570
- By:
- Publication type:
- Article
Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers.
- Published in:
- Journal of Clinical Pharmacology, 2004, v. 44, n. 5, p. 447
- By:
- Publication type:
- Article
Single Plasma Concentrations of 1'-Hydroxymidazolam or the Ratio of 1'-Hydroxymidazolam:Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2002, v. 42, n. 10, p. 1079, doi. 10.1177/009127002237986
- By:
- Publication type:
- Article
Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques.
- Published in:
- Journal of Clinical Pharmacology, 2002, v. 42, n. 4, p. 376, doi. 10.1177/0091270002424002
- By:
- Publication type:
- Article
Effects of Oral Vitamin K on S-and R-Warfarin Pharmacokinetics and Pharmacodynamics: Enhanced Safety of Warfarin as a CYP2C9 Probe.
- Published in:
- Journal of Clinical Pharmacology, 2001, v. 41, n. 7, p. 715, doi. 10.1177/009127000104100703
- By:
- Publication type:
- Article
A Dose-Ranging Study of Gentamicin Pharmacokinetics: Implications for Extended Interval Aminoglycoside Therapy.
- Published in:
- Journal of Clinical Pharmacology, 2001, v. 41, n. 4, p. 374, doi. 10.1177/009127000104100403
- By:
- Publication type:
- Article
A Study of the Pharmacokinetics of Azithromycin and Nelfinavir When Coadministered in Healthy Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2000, v. 40, n. 12, p. 1522, doi. 10.1177/009127000004001226
- By:
- Publication type:
- Article
The Absolute Bioavailability of Oral Melatonin.
- Published in:
- Journal of Clinical Pharmacology, 2000, v. 40, n. 7, p. 781, doi. 10.1177/00912700022009422
- By:
- Publication type:
- Article
Absence of Effect of Terbinafine on the Activity of CYP1A2, NAT-2, and Xanthine Oxidase.
- Published in:
- 1998
- By:
- Publication type:
- Other
Pharmacodynamics of Uniform versus Nonuniform Warfarin Dosages.
- Published in:
- Pharmacotherapy, 2008, v. 28, n. 6, p. 707, doi. 10.1592/phco.28.6.707
- By:
- Publication type:
- Article
The application of pharmacodynamics in the optimization of antibiotic therapy.
- Published in:
- Formulary, 2003, v. 38, n. 5, p. 294
- By:
- Publication type:
- Article
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the Shadows.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, p. S6, doi. 10.1002/jcph.1921
- By:
- Publication type:
- Article